IGC Pharma expands CALMA Phase 2 trial with Lynn Health Science Institute site

IGC Pharma (IGC) announced the expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, an investigational drug candidate for treating agitation in patients with Alzheimer’s disease. The Company has added a clinical site at the Lynn Health Science Institute in Oklahoma City, Oklahoma. Dr. Carl Griffin, MD, will serve as the Principal Investigator for the site. Dr. Griffin brings extensive experience in conducting clinical trials and a deep commitment to improving outcomes for patients affected by neurodegenerative diseases. He and the team at LHSI will begin recruiting eligible patients immediately. The CALMA trial is a randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the safety and efficacy of IGC-AD1 in reducing agitation in individuals diagnosed with Alzheimer’s disease. Agitation is one of the most challenging and disruptive symptoms associated with Alzheimer’s, often leading to earlier institutionalization and significant caregiver stress.